Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparin...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-04, Vol.25 (4), p.801-807 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 807 |
|---|---|
| container_issue | 4 |
| container_start_page | 801 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | Vermorken, J.B. Psyrri, A. Mesía, R. Peyrade, F. Beier, F. de Blas, B. Celik, I. Licitra, L. |
| description | Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status.
Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays.
Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients.
The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status. |
| doi_str_mv | 10.1093/annonc/mdt574 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3969553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419364968</els_id><sourcerecordid>1510712854</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-61167f0d5b2b6db4063c3c1d500354963e0f0dd965d87fbffbd46d7c3337603c3</originalsourceid><addsrcrecordid>eNqNkkGP1CAcxYnRuOvo0avhYuKlDgwtFA8mZjO6k6zRmNV4IxToFm2hC3R0PrFfQ2pnVz2YeCKE33v8eTwAHmP0HCNO1tI579R60Kli5R1wiivKixqV-C44RXxDClaR8gQ8iPELQojyDb8PTjZlxRjG7BT82A2jVAn6FqZp8AGev_8EY5JpitA76Kek_GCgdXCUyRqXIvxmUweDUVMIeQ-l0-usG0ySs84qGK8nOfhsoEzfQyWDss4P8tcdnYGdkXpWQWfU19nI2L11V1B1ZvAZCHI8LJdk23nNQ2SrNH23g2xeZEUKPo5GJbs32Uj2h2jjjfvYyWjgbreD28-XH7ZvtzAFK_uH4F4r-2geHdcV-Ph6e3l2Xly8e7M7e3VRqJLXqaAYU9YiXTWbhuqmRJQoorCuECJVySkxKJ9qTitds7Zp20aXVDNFCGEUZXYFXi6-49QMRqucUJC9GEOePRyEl1b8feJsJ678XhBOeVWRbPDsaBD89WRiEoONc5DSmZypwFVJOKeM1f-BYsTwps6KFSgWVOXoYjDt7UQYiblHYumRWHqU-Sd_PuOWvilOBp4eARmV7NsgnbLxN1cThCnmmWMLZ3Loe2uCiCrXSBlt888nob39xwg_Ac2W7RQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1510712854</pqid></control><display><type>article</type><title>Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Vermorken, J.B. ; Psyrri, A. ; Mesía, R. ; Peyrade, F. ; Beier, F. ; de Blas, B. ; Celik, I. ; Licitra, L.</creator><creatorcontrib>Vermorken, J.B. ; Psyrri, A. ; Mesía, R. ; Peyrade, F. ; Beier, F. ; de Blas, B. ; Celik, I. ; Licitra, L.</creatorcontrib><description>Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status.
Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays.
Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients.
The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdt574</identifier><identifier>PMID: 24577117</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic agents ; Biological and medical sciences ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - genetics ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - virology ; Cetuximab ; Cyclin-Dependent Kinase Inhibitor p16 - genetics ; Cyclin-Dependent Kinase Inhibitor p16 - isolation & purification ; Disease-Free Survival ; Female ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - genetics ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - virology ; Human papillomavirus ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - virology ; Original ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; p16 ; Papillomaviridae - genetics ; Papillomaviridae - isolation & purification ; Papillomaviridae - pathogenicity ; Pharmacology. Drug treatments ; Prognosis ; recurrent and metastatic ; squamous cell carcinoma of the head and neck ; Tumors ; Viral diseases</subject><ispartof>Annals of oncology, 2014-04, Vol.25 (4), p.801-807</ispartof><rights>2014 THE AUTHORS</rights><rights>2015 INIST-CNRS</rights><rights>The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-61167f0d5b2b6db4063c3c1d500354963e0f0dd965d87fbffbd46d7c3337603c3</citedby><cites>FETCH-LOGICAL-c498t-61167f0d5b2b6db4063c3c1d500354963e0f0dd965d87fbffbd46d7c3337603c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28301619$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24577117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vermorken, J.B.</creatorcontrib><creatorcontrib>Psyrri, A.</creatorcontrib><creatorcontrib>Mesía, R.</creatorcontrib><creatorcontrib>Peyrade, F.</creatorcontrib><creatorcontrib>Beier, F.</creatorcontrib><creatorcontrib>de Blas, B.</creatorcontrib><creatorcontrib>Celik, I.</creatorcontrib><creatorcontrib>Licitra, L.</creatorcontrib><title>Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status.
Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays.
Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients.
The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - virology</subject><subject>Cetuximab</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - genetics</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - isolation & purification</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - genetics</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - virology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - virology</subject><subject>Original</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>p16</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomaviridae - isolation & purification</subject><subject>Papillomaviridae - pathogenicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>recurrent and metastatic</subject><subject>squamous cell carcinoma of the head and neck</subject><subject>Tumors</subject><subject>Viral diseases</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkGP1CAcxYnRuOvo0avhYuKlDgwtFA8mZjO6k6zRmNV4IxToFm2hC3R0PrFfQ2pnVz2YeCKE33v8eTwAHmP0HCNO1tI579R60Kli5R1wiivKixqV-C44RXxDClaR8gQ8iPELQojyDb8PTjZlxRjG7BT82A2jVAn6FqZp8AGev_8EY5JpitA76Kek_GCgdXCUyRqXIvxmUweDUVMIeQ-l0-usG0ySs84qGK8nOfhsoEzfQyWDss4P8tcdnYGdkXpWQWfU19nI2L11V1B1ZvAZCHI8LJdk23nNQ2SrNH23g2xeZEUKPo5GJbs32Uj2h2jjjfvYyWjgbreD28-XH7ZvtzAFK_uH4F4r-2geHdcV-Ph6e3l2Xly8e7M7e3VRqJLXqaAYU9YiXTWbhuqmRJQoorCuECJVySkxKJ9qTitds7Zp20aXVDNFCGEUZXYFXi6-49QMRqucUJC9GEOePRyEl1b8feJsJ678XhBOeVWRbPDsaBD89WRiEoONc5DSmZypwFVJOKeM1f-BYsTwps6KFSgWVOXoYjDt7UQYiblHYumRWHqU-Sd_PuOWvilOBp4eARmV7NsgnbLxN1cThCnmmWMLZ3Loe2uCiCrXSBlt888nob39xwg_Ac2W7RQ</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Vermorken, J.B.</creator><creator>Psyrri, A.</creator><creator>Mesía, R.</creator><creator>Peyrade, F.</creator><creator>Beier, F.</creator><creator>de Blas, B.</creator><creator>Celik, I.</creator><creator>Licitra, L.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140401</creationdate><title>Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial</title><author>Vermorken, J.B. ; Psyrri, A. ; Mesía, R. ; Peyrade, F. ; Beier, F. ; de Blas, B. ; Celik, I. ; Licitra, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-61167f0d5b2b6db4063c3c1d500354963e0f0dd965d87fbffbd46d7c3337603c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - virology</topic><topic>Cetuximab</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - genetics</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - isolation & purification</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - genetics</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - virology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - virology</topic><topic>Original</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>p16</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomaviridae - isolation & purification</topic><topic>Papillomaviridae - pathogenicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>recurrent and metastatic</topic><topic>squamous cell carcinoma of the head and neck</topic><topic>Tumors</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vermorken, J.B.</creatorcontrib><creatorcontrib>Psyrri, A.</creatorcontrib><creatorcontrib>Mesía, R.</creatorcontrib><creatorcontrib>Peyrade, F.</creatorcontrib><creatorcontrib>Beier, F.</creatorcontrib><creatorcontrib>de Blas, B.</creatorcontrib><creatorcontrib>Celik, I.</creatorcontrib><creatorcontrib>Licitra, L.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vermorken, J.B.</au><au>Psyrri, A.</au><au>Mesía, R.</au><au>Peyrade, F.</au><au>Beier, F.</au><au>de Blas, B.</au><au>Celik, I.</au><au>Licitra, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>25</volume><issue>4</issue><spage>801</spage><epage>807</epage><pages>801-807</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Prognostic value in recurrent and/or metastatic (R/M) disease remains to be confirmed. This retrospective analysis of the EXTREME trial, comparing chemotherapy plus cetuximab with chemotherapy first line in R/M SCCHN, investigated efficacy and prognosis according to tumor p16 and HPV status.
Paired tissue samples were used: p16INK4A expression was assessed by immunohistochemistry, and HPV status determined in extracted DNA samples using oligonucleotide hybridization assays.
Altogether, 416 of 442 patients had tumor samples available for p16 and HPV: 10% of tumors were p16 positive and 5% were HPV positive. Adding cetuximab to chemotherapy improved survival, irrespective of tumor p16 or HPV status. This pattern remained in a combined analysis of p16 and HPV. p16 positivity and HPV positivity were associated with prolonged survival compared with p16 negativity and HPV negativity. Subgroup analysis of patients with oropharyngeal cancer demonstrated a similar pattern to all evaluable patients.
The results from this analysis suggest that p16 and HPV status have prognostic value in R/M SCCHN and survival benefits of chemotherapy plus cetuximab over chemotherapy alone are independent of tumor p16 and HPV status.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>24577117</pmid><doi>10.1093/annonc/mdt574</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-04, Vol.25 (4), p.801-807 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3969553 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic agents Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - virology Cetuximab Cyclin-Dependent Kinase Inhibitor p16 - genetics Cyclin-Dependent Kinase Inhibitor p16 - isolation & purification Disease-Free Survival Female Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - genetics Head and Neck Neoplasms - pathology Head and Neck Neoplasms - virology Human papillomavirus Humans Infectious diseases Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - virology Original Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology p16 Papillomaviridae - genetics Papillomaviridae - isolation & purification Papillomaviridae - pathogenicity Pharmacology. Drug treatments Prognosis recurrent and metastatic squamous cell carcinoma of the head and neck Tumors Viral diseases |
| title | Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A40%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20tumor%20HPV%20status%20on%20outcome%20in%20patients%20with%20recurrent%20and/or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20receiving%20chemotherapy%20with%20or%20without%20cetuximab:%20retrospective%20analysis%20of%20the%20phase%20III%20EXTREME%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Vermorken,%20J.B.&rft.date=2014-04-01&rft.volume=25&rft.issue=4&rft.spage=801&rft.epage=807&rft.pages=801-807&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdt574&rft_dat=%3Cproquest_pubme%3E1510712854%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1510712854&rft_id=info:pmid/24577117&rft_els_id=S0923753419364968&rfr_iscdi=true |